BCMA | International Myeloma Foundation

Reading data and making notes

Week in Review

May 28

April and May 2026: What's New in Myeloma?

researcher with pipette

Week in Review

April 30

March and April 2026: What's New in Myeloma? 

African-American female researcher in laboratory

Week in Review

March 26

February and March 2026: What's New in Myeloma? 

attendees of an ASH 2025 presentation

Week in Review

February 12

Dr. Joseph Mikhael's Top 10 Myeloma Abstracts from ASH 2025

Patel Immagine-1

January 16

Anitocabtagene Autoleucel iMMagine-1 Trial: Exceptional Safety and Durability in Relapsed Myeloma

team of healthcare professionals

Week in Review

December 18

November and December 2025: What's New in Myeloma?

imwg conferences series, week in review blog, part 2

Week in Review

July 3

Top Takeaways from the 2025 IMWG Conference Series: Making Sense of Treatment (Part 2 of 2)

ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with RRMM

January 28

ISB2001 A Groundbreaking Trispecific Antibody Shows Promise for Advanced Multiple Myeloma Patients

NLB Members presenting on myeloma

Week in Review

October 28

Top Takeaways from Facebook Live Q&A with IMF Nurse Leadership Board Members

Class comparison of BCMA-directed therapies in relapsed multiple myeloma

June 24

Class comparison of BCMA-directed therapies in relapsed multiple myeloma

Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results

June 6

Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma

Bispecific Antibodies: Using Different Targets to Destroy Multiple Myeloma

Emerging Therapies

September 14

Using Different Targets to Destroy Multiple Myeloma

Subscribe to BCMA

Give Where Most Needed